58. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
Background: This study assessed the postoperative morbidity
occurring in the first 30 days after radical gastrectomy by
comparing gastric cancer petients who did or did not receive the
FOLFOX7 regimen of neoadjuvant chemotherapy.
Methods: We completed a retrospective analysis of 377
patients after their radical gastrectomies were performed in our
department between 2005 and 2009. Two groups of patients
were studied: the SURG group received surgical treatment
immediately after diagnosis; the NACT underwent surgery after
2-6 cycles of Neoadjuvant chemotherapy.
Results: There were 267 patient in the SURG group and 110
patients in the NACT group. The NACT group had more
proximal tumours (P=0.000), more total/proximal gastrectomies
(P=0.000) and longer operative time (P=0.005) than the SURG
group. Morbidity was 10.0% in the NACT patients and 17.2%
in the SURG patients (P=0.075). There were two cases of
postoperative death, both in the SURG group (P=1.000). No
changes in the complications or mortality rate were observed
between the SURG and NACT groups.
Conclusions: The FOLFOX7 neoadjuvant chemotherapy is not
associated with increased postoperative morbidity, indicating
that the FOLFOX7 neoadjuvant chemotherapy is a safe choice
for the treatment of local advanced gastric cancer.
Key words
Gsatric cancer; neoadjuvant chemotherapy; complication; FOLFOX7; surgery